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Identification and activation 
of TLR4-mediated signalling 
pathways by alginate-derived 
guluronate oligosaccharide in 
RAW264.7 macrophages
Weishan Fang1, Decheng Bi1, Ruijin Zheng2, Nan Cai1, Hong Xu1, Rui Zhou1, Jun Lu  1,3, Min 
Wan4 & Xu Xu1
Alginate, a natural acidic polysaccharide extracted from marine brown seaweeds, is composed of 
different blocks of β-(1, 4)-D-mannuronate (M) and its C-5 epimer α-(1, 4)-L-guluronate (G). Alginate-
derived guluronate oligosaccharide (GOS) readily activates macrophages. However, to understand its 
role in immune responses, further studies are needed to characterize GOS transport and signalling. 
Our results show that GOS is recognized by and upregulates Toll-like receptor 4 (TLR4) on RAW264.7 
macrophages, followed by its endocytosis via TLR4. Increased expression of TLR4 and myeloid 
differentiation protein 2 (MD2) results in Akt phosphorylation and subsequent activation of both 
nuclear factor-κB (NF-κB) and mechanistic target of rapamycin (mTOR). Moreover, GOS stimulates 
mitogen-activated protein kinases (MAPKs); notably, c-Jun N-terminal kinase (JNK) phosphorylation 
depends on TLR4 initiation. All these events contribute to the production of inflammatory mediators, 
either together or separately. Our findings also reveal that GOS induces cytoskeleton remodelling in 
RAW264.7 cells and promotes macrophage proliferation in mice ascites, both of which improve innate 
immunity. Conclusively, our investigation demonstrates that GOS, which is dependent on TLR4, is taken 
up by macrophages and stimulates TLR4/Akt/NF-κB, TLR4/Akt/mTOR and MAPK signalling pathways 
and exerts impressive immuno-stimulatory activity.
Macrophages are important components of the innate immune system, playing a crucial role in host defence 
against infection through immuno-inflammatory responses, recognition of pathogens and phagocytosis. Indeed, 
the recognition and phagocytic capacities of macrophages are improved by secretion of pro-inflammatory fac-
tors1. However, the initial sensing of infection and strengthening of innate immunity are mediated by pattern rec-
ognition receptors (PRRs)2. As critical PRRs of host defence systems, Toll-like receptors (TLRs) are widely found 
on the surface of monocytes, macrophages and dendritic cells. TLRs are distinctly required for pathogen recogni-
tion by the innate immune system and mediate the production of inflammatory factors and also regulate immune 
responses3. Among TLRs, TLR4 acts as a receptor for lipopolysaccharide (LPS), and associates with the myeloid 
differentiation protein 2 (MD2) to form a complex to interact with LPS4. The formation of TLR4-MD2-LPS com-
plex activates the adaptor of myeloid differentiation factor 88 (MyD88) and drives pro-inflammatory signalling 
cascades, resulting in the activation of phosphatidylinositol-3-kinase (PI3K) and protein kinase B (Akt or PKB)5. 
It is reported that Akt participates in the nuclear factor-κB (NF-κB) signalling pathway to promote inflammatory 
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responses6. The mechanistic target of rapamycin (mTOR) pathway is also critical for signalling downstream of 
TLR4/Akt, playing roles in cell growth7 and immune regulation8. It has been demonstrated that both PI3K inhib-
itors and mTOR inhibitors can reduce LPS-stimulated cytokine secretion in RAW264.7 cells by decreasing Akt 
phosphorylation8. Furthermore, the mitogen-activated protein kinase (MAPK) pathway has a vital function in 
TLR4 signalling and subsequently the production of pro-inflammatory mediators3. Growing evidence suggests 
that polysaccharides and oligosaccharides from natural sources have potential as immunomodulators, with wide 
pharmacological applications, by recognizing macrophage cell surface receptors such as TLRs and initiating sig-
nal transduction and phagocytosis9, 10.
Alginate belongs to a family of natural acidic polysaccharides extracted from marine brown seaweeds. 
The molecule is composed of different blocks of β-(1, 4)-D-mannuronate (M) and its C-5 epimer α-(1, 
4)-L-guluronate (G)11, with three types of polymer blocks typically observed: polymannuronate (PM), polygulu-
ronate (PG) and a heteropolymer with random residues of M and G (PMG)12. Due to its beneficial bioactivities, 
alginate has been widely used as a food additive, cosmetic ingredient and pharmaceutical material13. With lower 
molecular weights and viscosities compared with the polymer, alginate oligosaccharide (AOS) appears to possess 
more physiological activities. For example, AOS prepared by oxidative degradation, which has a carboxyl group 
at the reducing end, displays anti-inflammatory and neuroprotective effects14, 15. Additionally, AOS prepared by 
enzymatic degradation, which has an unsaturated terminal structure with a C4-C5 double bond, exhibits various 
immuno-stimulation16, anti-tumour17, antioxidant and neuroprotective activities18. Among these activities, more 
attention has been paid to the macrophage immuno-inflammatory responses induced by unsaturated guluro-
nate oligosaccharide (GOS) derived from PG. GOS has been found to augment the release of cytokines, such as 
tumour necrosis factor-α (TNF-α)16, and to induce the production of nitric oxide (NO) by activating NF-κB and 
MAPK signalling pathways19 in RAW264.7 cells. GOS also promotes macrophage bactericidal activity by increas-
ing phagocytosis in vitro and in vivo20. Furthermore, proteomic analysis revealed that GOS improves macrophage 
homeostasis21. However, there is limited knowledge regarding the mechanism by which GOS regulates immune 
responses in macrophages, which warrants further investigation. The overall goal of the present study is to inves-
tigate GOS receptor recognition and transport into cells as well as the mechanisms of GOS-activated immune 
responses mediated by TLR4-involved signalling in RAW264.7 cells.
Results
Determination of endotoxin contamination and macrophage endocytosis of GOS. Our earlier 
studies have shown that GOS increases the production of pro-inflammatory mediators such as NO and TNF-α 
in RAW264.7 cells19. However, endotoxin (LPS) is also an effective inducer of inflammatory mediators. Thus, 
to eliminate potential false-positive results caused by endotoxin contamination, the GOS used in the current 
study was purified using an endotoxin-removal column. RAW264.7 macrophages were treated with GOS with 
or without polymyxin B (PMB), an LPS inhibitor, and NO production was evaluated. As shown in Fig. 1B, NO 
production by GOS-treated macrophages was not apparently affected by the presence of PMB. In contrast, LPS-
stimulated NO production was completely blocked by the addition of PMB, suggesting that the observed GOS-
induced macrophage activation was not due to endotoxin contamination.
Next, we labelled GOS with fluorescein isothiocyanate (FITC) and employed confocal laser scanning micros-
copy to examine whether FITC fluorescence labelled GOS (FITC-GOS) was taken up by macrophages. Weak 
FITC fluorescence appeared in RAW264.7 cells at 15 min after exposure to FITC-GOS, and fluorescence inten-
sity was markedly enhanced after 24 h. These results indicate that FITC-GOS was taken up by RAW264.7 cells 
in a time-dependent manner (Fig. 1C). We hypothesized that GOS is recognized by TLR4 on macrophages, 
therefore, to examine this possibility, we investigated the effect of a TLR4 inhibitor, ethyl (6 R)-6-[N-(2-chloro-
4-fluorophenyl) sulfamoyl] cyclohex-1-ene-1-carboxylate (TAK-242), on FITC-GOS endocytosis by RAW264.7 
macrophages. As shown in Fig. 1D, the fluorescence intensity was reduced by the addition of TAK-242, indicating 
that the inhibitor suppressed FITC-GOS endocytosis. However, intracellular FITC-GOS was not completely abol-
ished by TLR4 inhibition. These data reveal that GOS is taken up by macrophages via receptor-mediated endo-
cytosis and that TLR4 is a specific and important contributor but not the only receptor for GOS in this process.
Effect of GOS on TLR4 expression and TLR4/Akt signalling pathway activation. TLR4 partici-
pates in the transport of GOS into RAW264.7 cells. Accordingly, we further explored the impact of GOS on TLR4 
expression and TLR4-mediated signalling. Immunofluorescence staining revealed a notable increase in red flu-
orescence intensity for the GOS-treated group compared to the blank control group (Fig. 2A), and the intensity 
was quantified using ImageJ software. As shown in Fig. 2B, GOS-enhanced TLR4 fluorescence was statistically 
different from that of the control. Consistently, protein expression of TLR4, MD2 and MyD88 was upregulated by 
GOS treatment, as shown by Western blotting (Fig. 2C). Considering that GOS cannot alter CD14 expression in 
macrophages, which has been demonstrated by our previous publication20, we speculate that GOS could activate 
TLR4 and MD2, and trigger the MyD88-dependent pathway, leading to the production of pro-inflammatory 
cytokines without a requirement for CD14.
Our previous findings demonstrated that the upregulation of phosphorylated IκB induced by GOS is associ-
ated with NF-κB nuclear translocation20, we speculated that Akt phosphorylation contributes to GOS-stimulated 
signalling. As illustrated in Fig. 2D, the significant increase in Akt phosphorylation detected in GOS-treated 
samples supports a role for GOS in triggering Akt/NF-κB signalling. Furthermore, it was shown that GOS sig-
nificantly upregulated the phosphorylation levels of mTOR and p70 S6K, key downstream components of Akt 
signalling (Fig. 2E). Based on the data shown in Fig. 2D and E, we propose that GOS is a potential elicitor of the 
Akt/mTOR pathway.
Taken together, GOS upregulates TLR4 surface expression, followed by stimulation of PI3K and subsequent 
phosphorylation of Akt, resulting in NF-κB translocation into the nucleus and mTOR and p70 S6K activation. 
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We conclude that GOS activates macrophages through upregulation of TLR4, followed by Akt/NF-κB and Akt/
mTOR pathway activation.
Effect of TLR4 and PI3K inhibitors on GOS-activated Akt/NF-κB and Akt/mTOR signalling. 
To further determine whether the effects of GOS on the immune system depend on TLR4, PI3K/Akt and 
TLR4-related pathways, specific inhibitors for TLR4 and PI3K, TAK-242 and LY 294002, respectively, were applied. 
We found that pre-treatment of RAW264 cells with TAK-242 or LY 294002 suppressed GOS-induced p-Akt expres-
sion (Fig. 3A). Both TAK-242 and LY 294002 markedly inhibited GOS-mediated IκB phosphorylation and blocked 
nuclear translocation of p65 in the Akt/NF-κB pathway as well as phosphorylation of mTOR and p70 S6K in the 
Akt/mTOR pathway (Fig. 3B). In addition, GOS-induced upregulation of inducible nitric oxide synthase (iNOS) 
protein expression was reduced by TAK-242, LY 294002 and rapamycin, which are inhibitors of TLR4, PI3K and 
mTOR, respectively (Fig. 3C). GOS-induced NO and TNF-α production were also effectively arrested by the inhib-
itors (Fig. 3D and E). Our previous study showed that GOS-induced NO release could be suppressed by the NF-κB 
inhibitor pyrrolidinedithiocarbamate (PDTC)20. Taken together, Akt activation plays a key role in GOS-induced 
signalling transduction and is closely correlated to downstream NF-κB and mTOR signalling pathways.
Involvement of TLR4 in GOS-activated MAPK signalling. In our previous study, GOS was found 
to possess the ability to activate all MAPKs, including p38, c-Jun N-terminal kinase (JNK) and extracellular 
signal-regulated kinase (ERK)19. However, it remains unknown whether the phosphorylation of all MAPKs by 
GOS is mediated by TLR4 and related to the production of inflammatory factors. Therefore, we utilized TAK-
242 to examine the role of TLR4 in GOS-induced p38, JNK and ERK phosphorylation. As shown in Fig. 4A, the 
Figure 1. Endotoxin contamination tests and macrophage endocytosis of GOS. (A) Stereo-image of structure 
of alginate-derived GOS. (B) RAW264.7 cells were incubated with LPS (1 μg/ml, as a positive control) and GOS 
(1 mg/ml) in the presence or absence of the LPS inhibitor PMB (0.25 μg/ml) for 24 h. Nitrite levels in the culture 
medium of treated cells were measured using the Griess assay. (C) RAW264.7 cells were incubated with 1 mg/ml 
FITC-GOS for 15 min and 24 h and observed by laser scanning confocal microscopy (40x). (D) RAW264.7 cells 
were pre-incubated for 2 h with the TLR4 inhibitor TAK-242 (1 μM), then incubated with 1 mg/ml FITC-GOS 
for 22 h, and observed by laser scanning confocal microscopy (40x). Representative images and results from 
three independent experiments are shown. Scale bar = 20 μm. NS, no significance. **P < 0.01, ***P < 0.001.
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expression of only p-JNK was partly suppressed by TAK-242, whereas phosphorylation of p38 and ERK was 
not affected. Inhibitors of p38 (SB 20358), JNK (SP 600125) and ERK (PD 98059) were then applied to inves-
tigate the contribution of MAPKs in GOS-stimulated inflammatory mediator production. We determined that 
GOS-induced iNOS expression (Fig. 4B), NO release (Fig. 4C) and TNF-α secretion (Fig. 4D) were all signifi-
cantly suppressed by the three inhibitors. These data reveal that GOS increases phosphorylation of p38, JNK and 
ERK MAPKs, resulting in the production of NO and TNF-α. However, the phosphorylation of only JNK depends 
on TLR4 initiation after GOS recognition, and p38 and ERK are not mediated by TLR4.
Knockdown of TLR4 in RAW264.7 cells suppresses GOS-induced activation of signalling. To 
further confirm the role of TLR4 in RAW264.7 cells, we infected RAW264.7 cells with either lentivirus containing 
TLR4 shRNA or scramble shRNA. Compared with LPS- (positive control) or GOS-treated groups in the scram-
ble shRNA, TLR4 protein expressions in LPS- or GOS-treated groups of the TLR4 shRNA were significantly 
decreased, respectively (Fig. 5A). The p-p65 and p-mTOR protein expressions induced by LPS (positive control) 
or GOS were increased in the scramble shRNA group and were inhibited in TLR4 knockdown cells (TLR4 shRNA) 
(Fig. 5B and C). A similar trend was observed for p-JNK protein expression in RAW264.7 cells transfected with 
TLR4 shRNA (Fig. 5D). In addition, increases in LPS-induced or GOS-induced pro-inflammatory mediators such 
as iNOS (Fig. 5E), NO (Fig. 5F) and TNF-α (Fig. 5G) were partially inhibited with TLR4 gene knockdown. These 
data indicate that TLR4 plays a vital regulatory role in the macrophage activation induced by GOS. We speculate 
that GOS triggers immune response in macrophages depending on TLR4 and may interact with it.
Figure 2. GOS increases TLR4 expression and stimulates Akt/mTOR activation in RAW264.7 cells. 
(A) RAW264.7 cells were treated with 1 mg/ml GOS for 24 h, and TLR4 expression was evaluated by 
immunofluorescence analysis using an anti-TLR4 antibody. DAPI was used to label nuclei. Images were 
observed by laser scanning confocal microscopy (40x). (B) The average fluorescence intensity of forty cells of 
each treatment group was measured using ImageJ software. (C) RAW264.7 cells were incubated with LPS (1 μg/
ml, as a positive control) and GOS (1 mg/ml) for 24 h. The protein expression of TLR4, MD2 and MyD88 was 
detected by Western blotting. (D) Cells were treated with 1 μg/ml LPS (positive control) or 1 mg/ml GOS for 
24 h, and phosphorylated and nonphosphorylated Akt were detected by Western blotting. (E) Phosphorylation 
of mTOR and p70 S6K was analyzed by Western blotting. The full-length western blots were presented in 
supplementary information. Representative images and results from three independent experiments are shown. 
***P < 0.001.
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Effect of GOS on RAW264.7 cell cytoskeleton organization. mTOR pathway activation is involved 
in cytoskeleton remodelling and cell migration22. Thus, we hypothesized that GOS has the ability to remodel the 
cytoskeleton in RAW264.7 macrophages because it activates the Akt/mTOR pathway. We observed RAW264.7 
cells treated with GOS to be irregular or spindle-like in shape, with more extended pseudopodia (Fig. 6A). These 
changes in cell shape were quantified as cell aspect ratios (long side:short side) and the cell surface area using 
ImageJ software. Compared with blank control cells, GOS-treated cells showed significant increases in both cell 
aspect ratios and relative cell area (Fig. 6B and C).
Effect of GOS on macrophage proliferation in mouse peritoneum. Cell growth is closely correlated 
with cell proliferation in various organs, tissues, and even tumours, and is considered to be an mTOR-dependent 
process that is extremely sensitive to the mTOR inhibitor rapamycin7. To determine the effect of GOS on mac-
rophage proliferation, we treated male BALB/c mice with GOS via i.p. injection, collected primary macrophages 
from ascites, and determined the number (proportion) of macrophages using FACS. A pronounced increase 
in macrophage proportions was detected in GOS-treated mice compared to the control (Fig. 7A), and statis-
tical analysis of the fluorescence intensity showed a trend that was consistent with the flow cytometric plots 
(Fig. 7B). Therefore, we suggest that the increased number of peritoneal macrophages could effectively improve 
non-specific immunity, thereby boosting pathogen removal efficiency in mice.
In summary, our findings demonstrate that GOS can be taken up by RAW264.7 cells via endocytosis through 
TLR4. GOS stimulates macrophage activation via TLR4-related Akt/NF-κB, Akt/mTOR and MAPK pathways, 
followed by the production of NO and TNF-α, as illustrated in Fig. 8. Furthermore, GOS induces cytoskeleton 
remodelling to increase the cell aspect ratio and surface area. Additionally, GOS can also increase macrophage 
proliferation in mice ascites.
Figure 3. Inhibitors of TLR4 and PI3K suppress GOS-induced activation of Akt/NF-κB and Akt/mTOR 
pathways. (A) RAW264.7 cells were pre-incubated with the TLR4 inhibitor TAK-242 (1 μM) or PI3K inhibitor 
LY 294002 (10 μM) for 2 h and then co-treated with 1 mg/ml GOS for the indicated time. Akt phosphorylation 
was analyzed by Western blotting. (B) p-IκB, IκB and NF-κB p65 in the cytosolic fraction and p65 in the 
nuclear fraction were detected by Western blotting. Levels of phosphorylated and nonphosphorylated mTOR 
and p70 S6K were analyzed by Western blotting. (C) RAW264.7 cells were either pre-treated with the TLR4 
inhibitor TAK-242 (1 μM), PI3K inhibitor LY 294002 (10 μM) or mTOR inhibitor rapamycin (50 μM) for 2 h 
prior to GOS treatment or treated with inhibitors alone. iNOS protein expression was detected by Western 
blotting. The full-length western blots were presented in supplementary information. (D) Nitrite production in 
the culture supernatant of treated cells was measured by the Griess assay. (E) TNF-α in the culture supernatant 
from treated cells was measured by ELISA. LPS (1 μg/ml) was used as a positive control. Representative images 
and results from three independent experiments are shown. #Indicates significant differences between the 
control and GOS-treated groups, ###P < 0.001. *Indicates significant differences between the GOS-treated and 
GOS with inhibitor-treated groups, **P < 0.01, ***P < 0.001.
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Discussion
Endocytosis, a characteristic of macrophages, includes phagocytosis of bacteria or other large particles, pinocy-
tosis of colloids, and receptor-mediated endocytosis23. Multiple receptors, such as TLRs, Fcγ receptor (FcγR) and 
scavenger receptor (SR), have been found to activate signalling pathways and to be involved in endocytosis24. It 
was indicated that FITC-GOS was taken up by RAW264.7 cells (Fig. 1C). Our previous results demonstrated that 
pre-treatment with GOS could reduce LPS-stimulated cell morphological changes and damage21, suggesting that 
GOS is a potential competitive antagonist of macrophage cell surface receptors. Additionally, GOS has been found 
to activate NF-κB and MAPKs19, both of which are downstream of TLR4. Therefore, we hypothesized that GOS 
interferes with LPS via competitive interaction to macrophage cell surface receptors, such as TLR4, a well-known 
LPS-recognizing receptor. To examine this possibility, we selected TAK-242 which was reported to completely 
suppress the production of cytokine and nitric oxide (NO) induced by TLR4 ligand, as a TLR4 inhibitor, and 
investigated its effect on FITC-GOS endocytosis by RAW264.7 macrophages. As expected, we verified that GOS 
was taken up by macrophages via receptor-mediated endocytosis and GOS endocytosis was suppressed partially 
by TAK-242, indicating that TLR4 was a specific and important contributor but not the only receptor for GOS 
in this process (Fig. 1D). Previous studies have shown that GOS stimulated FcγRI and FcγRII expression on the 
macrophage surface, resulting in increased phagocytosis capacity20. Moreover, TLR2 activation by GOS was also 
evident in RAW264.7 cells16. Further investigations are needed to discover more macrophage cell surface recep-
tors to GOS.
Exogenous antigens such as polysaccharide enter cells by recognizing cell surface receptors, binding to which 
then activates downstream intracellular signalling to regulate immune responses9. As a critical member of the 
Figure 4. GOS activates the MAPK pathway. (A) RAW264.7 cells were pre-incubated with the TLR4 inhibitor 
TAK-242 (1 μM) and then co-treated with 1 mg/ml GOS for 15 min. Phosphorylated and nonphosphorylated 
p38, JNK and ERK were detected by Western blotting. (B) RAW264.7 cells were either pre-incubated with the 
p38 inhibitor SB 20358 (10 μM), JNK inhibitor SP 600125 (10 μM) or ERK inhibitor PD 98059 (10 μM) for 2 h 
prior to GOS treatment or treated with inhibitors alone. iNOS protein expression was assessed by Western 
blotting. The full-length western blots were presented in supplementary information. (C) Nitrite production in 
the culture supernatant of treated cells was measured by the Griess assay. (D) TNF-α in the culture supernatant 
of treated cells was measured by ELISA. LPS (1 μg/ml) was used as a positive control. Representative images and 
results from three independent experiments are shown. #Indicates significant differences between the control 
and GOS-treated groups, ###P < 0.001. *Indicates significant differences between the GOS-treated and GOS with 
inhibitor-treated groups, ***P < 0.001.
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TLR family, TLR4 has functions in activating innate immune cells and triggering inflammatory signal trans-
duction25. We also demonstrated that GOS enhanced TLR4 expression (Fig. 2A–C) and the inflammatory signal 
transduction triggered by GOS was partly suppressed in RAW264.7 cells with TLR4 gene knockdown (Fig. 5), 
suggesting that GOS may recognize and interact with TLR4.As reported by Nam et al., Akt phosphorylation 
activates IκB kinase (IKK), and the inhibitory protein (IκB) of NF-κB is then degraded by phosphorylated IKK 
through the ubiquitin proteasome pathway, resulting in the release of NF-κB and its translocation from the cyto-
plasm to the nucleus. NF-κB then initiates target gene expression and induces the production of inflammatory 
mediators including iNOS, NO and pro-inflammatory cytokines such as TNF-α, interleukin-1 (IL-1), and IL-626. 
Combined with our previous findings that the upregulation of phosphorylated IκB induced by GOS is associated 
with NF-κB nuclear translocation20, we speculated that Akt phosphorylation contributes to GOS-stimulated sig-
nalling. In addition, the Akt/mTOR signalling pathway is reported to participate in various processes, including 
cell growth, autophagy, apoptosis and immune regulation27, and activated Akt was found to induce expression 
of IL-6, TNF-α and IL-12 by initiating phosphorylation of mTOR and p70 S6K28. According to current findings 
(Figs 2D,E and 3), we propose that GOS-mediated immune regulation in RAW264.7 macrophages is divided into 
the following major steps: (1) GOS the surface receptor TLR4; (2) PI3K is activated by TLR4 and subsequently 
induces Akt phosphorylation; (3) phosphorylated Akt triggers IκB phosphorylation, resulting in (4) the release 
and translocation of NF-κB into the nucleus; (5) mTOR and p70 S6K are also activated by p-Akt; (6) all these 
factors work together or separately to induce the production of inflammatory mediators.
The MAPK pathway is one of the most important pathways downstream of TLR4, and it also contributes to 
immune responses by regulating the levels of TNF-α, IL-1β, IL-6, iNOS and NO29. An increasing number of 
studies in recent years have proven that various oligosaccharides, including chitosan oligosaccharide, alginate oli-
gosaccharide and rice bran feruloylated oligosaccharide, regulate immune functions via the MAPK pathway30–32. 
Figure 5. Knockdown of TLR4 with shRNA suppresses GOS-induced activation of signal transduction. 
(A) RAW264.7 cells were infected with lentivirus expressing either scramble shRNA or TLR4 shRNA. After 
treatment of LPS (1 μg/ml) (as a positive control) or GOS (1 mg/ml), TLR4 protein expression was detected 
by Western blotting. (B–D) Phosphorylated and nonphosphorylated p65 (B), mTOR (C) and JNK (D) were 
detected by Western blotting. (E) iNOS protein expression was assessed by Western blotting. The full-length 
western blots were presented in supplementary information. (F) Nitrite production in the culture supernatant 
of treated infected cells was measured by the Griess assay. (G) TNF-α in the culture supernatant of treated 
infected cells was measured by ELISA. Representative images and results from three independent experiments 
are shown, **P < 0.01, ***P < 0.001.
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Our previous results showed that GOS could activate all MAPKs, including p38, JNK and ERK19. In this study, 
we further conclude that GOS increases phosphorylation of MAPKs, followed by activation of downstream tran-
scription factors; as a consequence, gene transcription is initiated, which results in the production of NO and 
TNF-α. However, the phosphorylation of only JNK depends on TLR4 initiation after GOS recognition, and p38 
and ERK are not mediated by TLR4. It is known that various receptors, including TLR2, SR, mannose recep-
tor (MR), complement receptor (CR) and dectin-1, are also associated with the biological activities of polysac-
charides33, 34. Our previous studies also show that GOS can enhance the phagocytic function on macrophages 
by upregulating FcγII and FcγIII expression20. Therefore, we speculate that other GOS-recognizing receptors 
exist. Notably, TAK-242 can inhibit the LPS-induced phosphorylation of p38, JNK and ERK in RAW264.7 cells35, 
while TAK-242 suppresses the GOS-induced phosphorylation of only JNK, but not p38 and ERK (Fig. 4A). Our 
results here suggest that although GOS shares TLR4 with LPS in macrophage cell surface, their output signals are 
different.
mTOR pathway activation is involved in cytoskeleton remodelling and cell migration, whereby mTOR reg-
ulates the phosphorylation of the actin-remodelling proteins and downstream effector p70 S6K22. Pseudopod 
Figure 6. GOS induces changes in the morphology and cytoskeleton of RAW264.7 cells. (A) RAW264.7 cells 
were treated with 1 mg/ml GOS or medium alone (Ctrl) for 24 h and stained with FITC-phalloidin to visualize 
F-actin. Cell morphology was observed by laser scanning confocal microscopy (40x). Scale bar = 20 μm. GOS-
induced morphological changes including the cell aspect ratio (B) and cell area (C) were quantitatively analyzed 
using ImageJ software. ***P < 0.001.
www.nature.com/scientificreports/
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elongation, irregular shape and increased surface area have been described as common morphological changes 
induced in RAW264.7 cells by GOS or LPS. The observed changes in macrophage morphology caused by LPS 
were accompanied by distinct cytotoxicity characterized by loss of membrane integrity, a prominent nucleus and 
chromatin condensation21, 36. In contrast, the GOS-treated cells retained a healthy status, and GOS treatment 
reduced and repaired the morphological damage caused by LPS21. In addition, we have reported that GOS pro-
motes macrophage phagocytosis20. It appears that the increases in relative cell area and pseudopodia found in the 
current study can be beneficial for enhancing macrophage contacts with surrounding pathogens, which in turn, 
promotes their phagocytosis.
LPS as a component of the Gram-negative bacteria outer membrane, is the principal stimulator of the innate 
immune system37. TLR4 acts as a specific pattern-recognition receptor for LPS, and each of the target proteins 
involved in the TLR4 signalling pathway activated by LPS has been clarified clearly in the field of innate immune3. 
We used LPS as the positive control of this study. The influences of respectively LPS and GOS on signalling 
transduction in macrophages are different. Although LPS is recognized by TLR4, but they do not make contact 
directly. Firstly, LPS is recognized by lipopolysaccharide binding protein (LPB) and transported to the surface 
of macrophages with the help of LPB and CD14. MD2 and CD14 form a complex to interact with TLR438. Then, 
Figure 7. GOS induces macrophage proliferation in mice ascites. (A) Male BALB/c mice received an i.p. 
injection of 100 μl PBS or GOS (2 mg/mouse) for 24 h. Peritoneal fluid cells were collected and analyzed by 
FACS. (B) Data are expressed as the percentage of total cells and represent the means ± SD (n = 5). *P < 0.05.
Figure 8. Signalling pathways involved in the macrophage activation effect of alginate-derived guluronate 
oligosaccharide.
www.nature.com/scientificreports/
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the formation of TLR4-MD2-CD14-LPS complex activates MyD88 and drives pro-inflammatory signalling 
cascades, resulting in the activation of PI3K and Akt5. It has been reported that LPS can increase the expres-
sion of TLR4, MD2, CD14 and MyD8839, 40. We also found that GOS enhanced the expression of TLR4, MD2 
and MyD88 (Fig. 2C), but it did not alter the expression of CD1420. It is indicated that both LPS and GOS can 
stimulate TLR4 and MD2, and trigger the MyD88-dependent pathway, subsequently inducing the production of 
pro-inflammatory cytokines. CD14 is required for above process activated by LPS, but it is not required for that 
by GOS. MD2 is normally regarded as TLR4 co-receptor molecule41. The expression of MD2 was upregulated by 
GOS, but the function of MD2 in signalling transduction induced by GOS is still unknown.
In this study, we come to a conclusion that GOS stimulates the surface receptor TLR4 and its downstream 
PI3K/Akt/NF-κB and PI3K/Akt/mTOR signalling pathways. Mounting evidences show that LPS also induces 
above signalling transduction process via recognition of TLR43. Both LPS and GOS can increase phosphorylation 
of MAPKs. All these factors work together or separately to induce the production of inflammatory mediators 
triggered by LPS and GOS. Although GOS shares TLR4 with LPS in macrophage cell surface, their output signals 
are a little bit different. For example, the phosphorylation of only JNK depends on TLR4 initiation after GOS 
treatment, and p38 and ERK are not mediated by TLR4 (Fig. 4A), while the phosphorylations of p38, JNK and 
ERK increased by LPS are all dependent on TLR435. Combined with previous reports by our group20 and other 
authors16, other GOS-recognizing receptors exist, including FcγII, FcγIII and TLR2. Other potential receptors are 
necessary to be investigated to clarify the whole mechanism of GOS-induced immune response in macrophages 
in the further study.
Our study provides convincing evidence of the beneficial effects of GOS on the activation of macrophages via 
TLR4-mediated signalling. We believe that our study is the first to investigate that TLR4 serves as a specific and 
decisive contributor to GOS endocytosis into macrophages. Considering that GOS is derived from an abundant 
natural source, GOS is a promising food or medicine additive to potentially serve as an immune enhancer with 
unique immunomodulatory capabilities.
Methods
Materials. Alginate, LPS, PMB, FITC-phalloidin, FITC-LPS and 4′,6-diamidino-2-phenylindole (DAPI) were 
obtained from Sigma-Aldrich (St. Louis, MO, USA). RPMI-1640 medium, Dulbecco’s modified Eagle’s medium 
(DMEM), penicillin and streptomycin were purchased from Hyclone (Logan, UT, USA). Foetal bovine serum 
(FBS) was obtained from Biological Industries (Beit-Haemek, Israel). Anti-mouse TLR4, MD2, MyD88, F4/80 
and Ly6G antibodies were from purchased Abcam (Cambridge, UK). Antibodies against Akt, phosphor-Akt 
(p-Akt), NF-κB p65, IκB, phosphor-IκB (p-IκB), mTOR, phosphor-mTOR (p-mTOR), p70 S6 kinase (p70 S6K), 
phosphor-p70 S6K (p-p70 S6K), p38, phosphor-p38 (p-p38), JNK, phosphor-JNK (p-JNK), ERK, phosphor-ERK 
(p-ERK) and iNOS were purchased from Cell Signaling Technology (Beverly, MA, USA). Anti-β-actin, -β-tubu-
lin, -GAPDH and -Lamin B1 antibodies were purchased from Proteintech (Hubei, China). Inhibitors LY 294002, 
SB 20358, SP 600125 and PD 98059 were obtained from Selleck (Shanghai, China) and TAK-242 and rapamy-
cin from Invitrogen (Carlsbad, CA, USA). The other chemicals were all purchased from Macklin Biochemical 
Technology (Shanghai, China).
Preparation of GOS and FITC-GOS. GOS was depolymerized from PG using alginate lyase, as described 
previously20. The GOS molecular weight and degree of polymerization were determined by electrospray ion-
ization mass spectrometry (ESI-MS). GOS was found to be composed of α-L-guluronate dimer to octamer 
(G2-G8)21 (Fig. 1A). To reduce endotoxin levels below the limit of detection, the GOS used in the present study 
was pre-treated with Detoxi-GelTM Endotoxin Removing Columns (Thermo Scientific, Hudson, NH, USA).
For endocytosis studies, GOS was conjugated to FITC. GOS was dissolved in 2 M ethylenediamine in 
10% acetic acid and mixed with 4 M sodium cyanoborohydride at 45 °C overnight in the dark. After dialyz-
ing against distilled water, the dialysate was mixed with 10 mg/ml FITC-methanol solution for 24 h in the dark. 
The FITC-conjugated oligosaccharide was precipitated from the liquid using excess 95% ethanol, centrifuged 
at 3,500 rpm for 10 min, re-suspended, dialyzed, and freeze-dried. FITC-GOS was examined using thin layer 
chromatography (TLC) aluminium sheets (Silica Gel 60; Merck, Germany), and FITC-GOS fluorescence was 
confirmed using a camera obscura ultraviolet analyzer (Yuhua Instruments Equipment Co., Ltd., Henan, China).
Cell culture. Murine macrophage RAW264.7 cells were maintained in RPMI-1640 medium; human embry-
onic kidney (HEK293FT) cells were cultured in DMEM. The media were supplemented with 10% FBS, 100 μg/
ml streptomycin and 100 IU/ml penicillin, and the cells were grown in an incubator at 37 °C with a humidified 
5% CO2 atmosphere.
Lentivirus construction and infection. Scramble short-hairpin RNAs (shRNA) and shRNAs targeting 
nucleotides 1246–1264 of the mouse TLR4 mRNA were annealed and cloned into the GV248 lentiviral vec-
tor. The sequences were as follows: scramble shRNA, 5′-TTCTCCGAACGTGTCACGT-3′; TLR4 shRNA, 
5′-CATCATTATGAGTGCCAAT-3′. HEK293FT cells were infected with the TLR4 shRNA or scramble shRNA 
vector along with viral packaging plasmids (pLP1, pLP2 and pLP-VSVG) using Lipofectamine 3000 (Invitrogen, 
CA, USA) to produce retroviral particles. The retroviral particles were collected and purified on days 2 and 3 after 
infection. RAW264.7 cells were then infected with the retroviruses containing TLR4 shRNA or scramble shRNA 
in the presence of polybrene. Puromycin-resistant clones were selected, and TLR4 protein expression levels were 
detected by Western blot analysis.
Measurement of NO production. Adherent RAW264.7 cells in 96-well plates (2 × 105 cells/well) were 
pre-treated with vehicle or various concentrations of individual inhibitors for 2 h in serum-free RPMI-1640 
medium, followed by co-culture with 1 μg/ml LPS (positive control) or 1 mg/ml GOS for an additional 22 h. Next, 
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50 μl of culture supernatant from each well was mixed with 100 μl of Griess reagent [1% sulfanilamide, 0.1% N- 
(1-naphthyl)-ethylenediamine dihydrochloride, and 2.5% phosphoric acid] and incubated at room temperature 
(RT) for 5 min. Sodium nitrite was used to construct a standard curve. Nitrite production was evaluated by meas-
uring absorbance at 540 nm using a Spectra Max microplate reader (Thermo Scientific, Hudson, NH, USA).
Western blot analysis. After various treatments, cells were washed with phosphate-buffered saline (PBS) 
and lysed with RIPA buffer (Beyotime Institute Biotech, Jiangsu, China) on ice for 25 min. The supernatant was 
collected after centrifuging at 12,000 × g at 4 °C for 30 min, and nuclear and cytoplasmic fractions were separated 
using a nuclear extraction kit according to the manufacturer’s protocol. The protein content was assessed using 
the BCA assay (Auragene Biosciences, Hunan, China). Protein (30 μg) for each sample was loaded, separated by 
8% or 12% sodium dodecyl sulfonate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to pol-
yvinylidene fluoride (PVDF) membranes. The membranes were blocked with 5% skim milk at RT for 2 h and 
incubated overnight with primary antibodies (1:1000) at 4 °C. After washing three times with TBS containing 
0.5% Tween 20 (TBST), the membranes were treated with the corresponding secondary antibody at 37 °C for 2 h. 
After washing three times with TBST, densitometric analysis of each protein was carried out using a chemilumi-
nescence (ECL) kit (Thermo Scientific, Hudson, NH, USA).
Measurement of TNF-α secretion. Adherent RAW264.7 cells in 96-well plates (2 × 105 cells/well) 
were pre-treated with vehicle or various concentrations of individual inhibitors for 2 h in serum-free RPMI-
1640 medium, followed by co-culture with 1 mg/ml GOS for an additional 22 h. The culture supernatants were 
collected, and the levels of TNF-α were measured using an ELISA kit (Neobioscience Technology Company, 
Guangdong, China) following the manufacturer’s instructions.
Determination of macrophage endocytosis of FITC-GOS. RAW264.7 cells (6 × 105 cells/well) were 
seeded onto 6-well chamber slides. After 4 h, the cells were treated with medium alone or 1 mg/ml FITC-GOS 
for 15 min or 24 h. To evaluate the role of TLR4 in GOS endocytosis, the cells were pre-treated with 1 μM TLR4 
inhibitor (TAK-242) for 2 h and then co-incubated with FITC-GOS for 22 h. Next, the cells were fixed with 4% 
paraformaldehyde in PBS and observed using laser scanning confocal microscopy (Carl Zeiss Jena Gmbh, Jena, 
Germany).
Immunofluorescence analysis. RAW264.7 cells (6 × 105 cells/well) were cultured on 6-well chamber slides 
and treated with PBS, 1 μg/ml FITC-LPS (positive control) or 1 mg/ml FITC-GOS for 24 h. The cells were fixed 
with 4% paraformaldehyde in PBS at RT. After washing with PBS, the cells were permeabilized with 0.2% Triton 
X-100 in PBS at RT for 30 min. After 60 min of blocking with 1% (w/v) goat serum in PBS at 37 °C, the cells were 
incubated with an anti-TLR4 antibody diluted in PBS (1:200) on ice overnight, washed three times with ice-cold 
PBS, and stained with an Alexa Fluor 488-conjugated secondary anti-mouse antibody at 37 °C for 2 h. Nuclei were 
counterstained with DAPI for 15 min. Fluorophores were visualized using laser scanning confocal microscopy, 
and the images were analyzed using ImageJ software (National Institutes of Health, Bethesda, MD, USA).
Morphological analysis. RAW264.7 cells (6 × 105 cells/well) on 6-well chamber slides were treated with 
medium alone or 1 mg/ml GOS for 24 h. The cells were fixed with 4% paraformaldehyde and mixed with 0.2% 
Triton X-100 for 30 min at RT. After washing three times with PBS, the cells were stained with FITC-phalloidin 
for 1 h, followed by DAPI staining for 10 min. Morphological changes were monitored by laser scanning confocal 
microscopy, and the images were analyzed using ImageJ software.
In vivo determination of macrophage proliferation. Male seven-week-old BALB/c mice were pur-
chased from Guangdong Laboratory Animals Monitoring Institute (Guangzhou, Guangdong, China) and fed in 
a specific pathogen free (SPF) environment. The animal experiments were approved by the Institute of Marine 
Biotechnology at Shenzhen University according with relevant guidelines and regulations. The mice were received 
an intraperitoneal (i.p.) injection of 100 μl PBS or GOS (2 mg/mouse). After 24 h, the mice were killed, and the 
peritoneal cavity was lavaged with 500 μl sterile PBS containing 5 μM EDTA. The lavage fluid was collected, and 
the cells were washed and re-suspended in 100 μl PBS containing 1% BSA. Next, the cells (1 × 106) were treated 
with fluorescently conjugated anti-F4/80 and anti-Ly6G antibodies on ice for 60 min, collected and resuspended 
in PBS. Finally, the cells were examined by flow cytometry (FACS), and the data were analyzed using FACSDiva 
software (Becton Dickinson, San Jose, CA, USA). Cells were considered to be macrophages on the basis of F4/80+ 
and Ly6G− 42, 43.
Statistical analysis. All experiments were repeated at least three times (n ≥ 3). The data for all experiments 
are presented as the means ± standard deviation (SD), and the results were analyzed using two-tailed Student’s 
t-test to determine significant differences. A value of p < 0.05 was considered statistically significant.
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